CY1116919T1 - Διαδικασια παρασκευης οξινης θειικης αταζαναβιρης και καινοτομων μορφων - Google Patents

Διαδικασια παρασκευης οξινης θειικης αταζαναβιρης και καινοτομων μορφων

Info

Publication number
CY1116919T1
CY1116919T1 CY20151101005T CY151101005T CY1116919T1 CY 1116919 T1 CY1116919 T1 CY 1116919T1 CY 20151101005 T CY20151101005 T CY 20151101005T CY 151101005 T CY151101005 T CY 151101005T CY 1116919 T1 CY1116919 T1 CY 1116919T1
Authority
CY
Cyprus
Prior art keywords
atazanavir
hydrogen sulfate
preparation
crystals
sulfur
Prior art date
Application number
CY20151101005T
Other languages
English (en)
Inventor
Soojin Kim
Bruce T Lotz
Mary F Malley
Jack Z Gougoutas
Martha Davidovich
Sushil K Srivastava
Original Assignee
Bristol-Myers Squibb Holdings Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35310244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116919(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Holdings Ireland filed Critical Bristol-Myers Squibb Holdings Ireland
Publication of CY1116919T1 publication Critical patent/CY1116919T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/127—Preparation from compounds containing pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Παρέχεται κάποια διαδικασία για την παρασκευή του αναστολέα της πρωτεάσης ΗIV, της όξινης θειικής αταζαναβίρης, όπου διάλυμα ελεύθερης βάσης της αταζαναβίρης αντιδρά με πυκνό θειικό οξύ σε ποσότητα τέτοια ώστε να αντιδράσει με λιγότερο από το 15% περίπου κατά βάρος της ελεύθερης βάσης, την προσθήκη πυρήνων κρυστάλλων Μορφής Α όξινης θειικής αταζαναβίρης στο μείγμα αντίδρασης, και ως κρύσταλλοι της όξινης θειικής μορφής, την προσθήκη επιπρόσθετης ποσότητας πυκνού θειικού οξέος σε πολλαπλά στάδια με αυξανόμενο ρυθμό σύμφωνα με κάποια κυβική εξίσωση, ώστε να έχει επίδραση στο σχηματισμό κρυστάλλων όξινης θειικής αταζαναβίρης Μορφής Α. Επίσης παρέχεται κάποια διαδικασία για την παρασκευή όξινης θειικής αταζαναβίρης ως υλικό Σχηματομορφής C. Παρέχεται επίσης κάποια καινοτόμος μορφή όξινης θειικής αταζαναβίρης, η οποία είναι Μορφής Ε3, η οποία είναι εξαιρετικά κρυσταλλικό επιδιαλυτωμένο χημικό σωματίδιο τριαιθανολικού του όξινου θειικού άλατος από αιθανόλη.
CY20151101005T 2004-05-04 2015-11-10 Διαδικασια παρασκευης οξινης θειικης αταζαναβιρης και καινοτομων μορφων CY1116919T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56804304P 2004-05-04 2004-05-04
US60753304P 2004-09-07 2004-09-07
US11/119,558 US7829720B2 (en) 2004-05-04 2005-05-02 Process for preparing atazanavir bisulfate and novel forms
EP05744537.1A EP1755596B9 (en) 2004-05-04 2005-05-03 Process for preparing atazanavir bisulfate and novel forms

Publications (1)

Publication Number Publication Date
CY1116919T1 true CY1116919T1 (el) 2017-04-05

Family

ID=35310244

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151101005T CY1116919T1 (el) 2004-05-04 2015-11-10 Διαδικασια παρασκευης οξινης θειικης αταζαναβιρης και καινοτομων μορφων

Country Status (20)

Country Link
US (3) US7829720B2 (el)
EP (3) EP1755596B9 (el)
JP (1) JP5086069B2 (el)
KR (1) KR101153606B1 (el)
AU (2) AU2005240622B2 (el)
BR (1) BRPI0509595B8 (el)
CA (2) CA2777216A1 (el)
CY (1) CY1116919T1 (el)
DK (1) DK1755596T5 (el)
ES (1) ES2552219T3 (el)
HR (1) HRP20150962T2 (el)
HU (1) HUE026242T2 (el)
IL (1) IL178965A (el)
MX (1) MXPA06012612A (el)
NO (1) NO341013B1 (el)
PL (1) PL1755596T3 (el)
PT (1) PT1755596E (el)
RS (1) RS54284B1 (el)
SI (1) SI1755596T1 (el)
WO (1) WO2005108349A2 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
US7642049B2 (en) 2006-06-30 2010-01-05 Bristol-Myers Squibb Company Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms
BRPI0823520A2 (pt) 2007-06-12 2013-12-17 Concert Pharmaceuticals Inc Composto derivado de azapeptídeos e composição farmacêutica contendo o mesmo
EP2178512B1 (en) * 2007-06-22 2011-03-09 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
DE602008005316D1 (de) * 2007-06-22 2011-04-14 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
PT2170292E (pt) * 2007-06-22 2014-03-06 Bristol Myers Squibb Holdings Ireland Composições de comprimido contendo atazanavir
SI2178513T1 (sl) * 2007-06-22 2011-05-31 Bristol Myers Squibb Co Tabletni sestavki vsebujoäśi atazanavir
EP2376452A4 (en) 2009-01-12 2012-08-29 Hetero Research Foundation NEW SULFATE POLYMORPH OF ATAZANAVIR
WO2011027324A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Polymorphic forms of atazanavir sulfate
PL2493312T3 (pl) 2009-10-26 2022-01-03 Merck Sharp & Dohme Corp. Kompozycje farmaceutyczne w postaci ciała stałego zawierające inhibitor integrazy
EP2555757B1 (en) 2010-04-09 2016-05-25 Bristol-Myers Squibb Holdings Ireland Atazanavir sulfate formulations with improved ph effect
EP2621472A1 (en) 2010-09-28 2013-08-07 Ratiopharm GmbH Dry processing of atazanavir
US20140343290A1 (en) 2011-07-27 2014-11-20 Rakesh Kumar Singh Process for the preparation of atazanavir or its bisulfate salt
US8461347B2 (en) 2011-08-05 2013-06-11 Scinopharm Taiwan, Ltd. Process for preparing form A of atazanavir sulfate
EP2888230A4 (en) * 2012-08-24 2017-07-19 Laurus Labs Private Limited Improved process for the preparation of atazanavir bisulfate
WO2014036690A1 (zh) * 2012-09-04 2014-03-13 上海迪赛诺化学制药有限公司 制备阿扎那韦硫酸氢盐a型结晶的方法
US9890121B2 (en) * 2013-02-12 2018-02-13 Cipla Limited Process for preparing atazanavir sulphate
CN115215792A (zh) * 2022-06-27 2022-10-21 江西富祥药业股份有限公司 一种制备阿扎那韦或其硫酸盐的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658435A (en) * 1900-03-22 1900-09-25 William T Ginn Coal-digger.
US4022776A (en) 1974-01-31 1977-05-10 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxycarbostyril derivatives
US3980637A (en) 1975-03-17 1976-09-14 Bristol-Myers Company Production of amoxicillin
DE3403329A1 (de) 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
JPS6186211A (ja) 1984-10-04 1986-05-01 日本碍子株式会社 セラミックス複合構造体及びその製造法
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5158777A (en) 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5428048A (en) 1993-11-08 1995-06-27 American Home Products Corporation Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
TW483763B (en) 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
KR100486051B1 (ko) * 1996-04-22 2005-09-09 노파르티스 아게 항바이러스활성헤테로시클릭아자헥산유도체
GB9715896D0 (en) 1997-07-28 1997-10-01 Sca Packaging Ltd Containers
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
WO2000056719A1 (en) 1999-03-22 2000-09-28 Bristol-Myers Squibb Company FUSED PYRIDOPYRIDAZINE INHIBITORS OF cGMP PHOSPHODIESTERASE
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
WO2001034148A1 (fr) 1999-11-11 2001-05-17 Kyorin Pharmaceutical Co., Ltd. Preparations solides pour administration orale
ES2433476T3 (es) 2000-01-21 2013-12-11 Novartis Ag Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes 5 antidiabéticos
US6254888B1 (en) 2000-01-28 2001-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Method for coating pharmaceutical dosage forms
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
YU34501A (sh) 2000-05-26 2003-10-31 Pfizer Products Inc. Postupak reaktivne kristalizacije radi povećanja veličine čestica
IL145106A0 (en) 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US6670344B2 (en) 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
CA2444569C (en) 2001-04-18 2011-01-04 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
MXPA04006892A (es) 2002-01-15 2004-10-15 Ranbaxy Lab Ltd Composiciones farmaceuticas estables que comprenden inhibidor(es) ace.
KR100456833B1 (ko) 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
TW200534879A (en) 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US7829720B2 (en) 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050256314A1 (en) 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US20050288343A1 (en) 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法

Also Published As

Publication number Publication date
EP1755596B1 (en) 2015-08-12
SI1755596T1 (sl) 2015-10-30
BRPI0509595B8 (pt) 2021-05-25
EP1755596B9 (en) 2016-02-10
WO2005108349A2 (en) 2005-11-17
WO2005108349A3 (en) 2006-11-02
US7829720B2 (en) 2010-11-09
AU2005240622A1 (en) 2005-11-17
IL178965A0 (en) 2007-03-08
EP2669273A1 (en) 2013-12-04
HUE026242T2 (en) 2016-06-28
JP2007536245A (ja) 2007-12-13
RS54284B1 (en) 2016-02-29
NO341013B1 (no) 2017-08-07
BRPI0509595B1 (pt) 2019-05-14
PT1755596E (pt) 2015-11-19
CA2777216A1 (en) 2005-11-17
JP5086069B2 (ja) 2012-11-28
IL178965A (en) 2011-05-31
HRP20150962T2 (hr) 2016-04-08
CA2565629A1 (en) 2005-11-17
US20090203630A1 (en) 2009-08-13
KR20070006935A (ko) 2007-01-11
DK1755596T3 (en) 2015-11-16
AU2010201538A1 (en) 2010-05-13
US8513428B2 (en) 2013-08-20
HRP20150962T1 (en) 2015-10-09
ES2552219T3 (es) 2015-11-26
CA2565629C (en) 2012-07-31
US20050256202A1 (en) 2005-11-17
EP1755596A2 (en) 2007-02-28
MXPA06012612A (es) 2006-12-15
PL1755596T3 (pl) 2016-04-29
DK1755596T5 (en) 2016-05-23
EP1755596A4 (en) 2010-12-29
NO20065441L (no) 2006-11-27
US20110124689A1 (en) 2011-05-26
KR101153606B1 (ko) 2012-06-11
EP2980074A1 (en) 2016-02-03
AU2005240622B2 (en) 2010-02-11
AU2010201538B2 (en) 2012-09-06
BRPI0509595A (pt) 2007-10-16
US7838678B2 (en) 2010-11-23

Similar Documents

Publication Publication Date Title
CY1116919T1 (el) Διαδικασια παρασκευης οξινης θειικης αταζαναβιρης και καινοτομων μορφων
ES2426063T3 (es) Métodos para sintetizar borano de amoniaco
TW200600498A (en) Process for preparing atazanavir bisulfate and novel forms
CY1106837T1 (el) Μεθοδος παραγωγης κρυσταλλων νατεγλινιδιου
IL190694A (en) A method for obtaining unnatural amino acid and a reaction mixture for this purpose
DK1462442T3 (da) Krystaller af bicalutamid og fremgangsmåde til deres fremstilling
MY126689A (en) Process for the preparation of sulphonamide-substituted imidazotriazinones
Davis et al. Thermochromism of two disulfides
DE502006003346D1 (de) Verfahren zur herstellung von beta-aminopropionsäurederivaten
AR053759A1 (es) Procedimiento para preparar acido cianhidrico
BR0210761B1 (pt) processo para preparar uma solução de hidroxilamina aquosa, isenta de sal.
TW200624422A (en) Process for production of 2-chloro-4-nitroimidazole
Shefer et al. General, fast, and high yield oxidation of thiols and disulfides to sulfonic and sulfinic acids using HOF· CH3CN
Glover Development of the HERON reaction: A historical account
US6753446B1 (en) Synthesis of labeled oxalic acid derivatives
CA2549947A1 (en) Process for producing ammonium polythiomolybdate
CN105175286B (zh) 一种盐酸烷基胍盐的制备方法
MD3684G2 (ro) Procedeu de obţinere a N, N-dialchiltioureidoacetofenonelor
BR0312773A (pt) Método para produzir um composto altamente puro
BR0311246A (pt) Processo para produção de amidas de ácido 4-haloalquilnicotìnico
Spillane et al. Mechanism of the acid-catalyzed hydrolysis of N-acylsulfamates
Bao et al. Data on the convenient fabrication of carbon doped WO3− x ultrathin nanosheets for photocatalytic aerobic oxidation of amines at room temperature
HUP0302174A2 (hu) Eljárás királisan tiszta N-(transz-4-izopropil-ciklohexilkarbonil)-D-fenilalanin (Nateglinid) és kristálymódosulatainak előállítására, valamint a G kristálymódosulata
PL429462A1 (pl) Sposób otrzymywania nadkwasu n-dekadowego
MX2022016308A (es) Base de schiff de boro (boschiba) con grupos terbutilos y su uso como agentes fluorescentes en bioimagen celular.